企業概要
Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology entity dedicated to the research, development, and commercialization of therapeutic solutions specifically designed for the management of chronic wounds. Within the broader Healthcare sector, the company operates within the specialized industry of Medical Instruments & Supplies, focusing on the manufacturing and distribution of medical-grade sterile blowfly larvae bio-dressing products utilized as a biological treatment modality. The firm maintains a very small operational scale with a total of 14 employees and a current market capitalization of $7.58 million, while reporting trailing twelve-month revenue of $30,331. These financial metrics indicate that the company functions as a micro-cap entity with minimal revenue generation relative to its market valuation, suggesting a capital-intensive business model where significant market cap exists despite negligible annual sales figures.
財務健全性
The company reported trailing twelve-month revenue of $30,331 against a net income of -$2,831,603 and an EBITDA of -$2,810,243, revealing a profound structural cost burden where expenses vastly outweigh revenue generation. The free cash flow stands at -$7,248,589, indicating a severe lack of financial flexibility as the firm is currently burning cash at a rate far exceeding its minimal cash reserves of $4.17 million. The gross margin is recorded at -69.2%, the operating margin at -8643.0%, and the profit margin at 0.0%, collectively signaling that the company's cost of goods sold and operational overheads are disproportionately high relative to its sales volume, resulting in substantial losses on every unit sold. The balance sheet reflects a leveraged position with total debt of $3.14 million against cash of $4.17 million, supported by a debt-to-equity ratio of 40.86, which suggests the company carries significant long-term obligations relative to its shareholder equity despite holding some liquid assets. Short-term liquidity is supported by a current ratio of 3.58, which technically indicates the ability to cover short-term liabilities with current assets, though this metric may be inflated by the nature of the assets held or the specific composition of current liabilities in this micro-cap context. Return on Equity is -139.1% and Return on Assets is -28.4%, metrics that reveal management is currently destroying shareholder value and failing to generate sufficient returns on the capital employed in the business.
バリュエーション評価
The trailing P/E ratio is listed as N/A and the forward P/E is also N/A, implying that the market cannot value the stock based on earnings multiples due to the absence of positive reported earnings or projected profitability in the near term. The price-to-book ratio stands at 1.27, indicating that the stock is trading at a slight premium of 27% over its book value, a valuation characteristic often seen in speculative biotech firms where intangible assets or future potential outweigh current tangible equity. Alternative valuation metrics such as the price-to-sales ratio of 249.85 and an EV/EBITDA of -2.33 suggest that investors are pricing the company based on asset backing and potential rather than current profitability or sales performance, reflecting extreme valuation compression relative to revenue. The 52-week price range spans from a low of $0.28 to a high of $9.50, placing the current trading context within a highly volatile band where the stock has experienced a massive expansion from its lowest point. The beta is listed as N/A, meaning that the historical price volatility relative to the broader market cannot be quantified through standard statistical measures, likely due to the limited trading volume or the absence of a sufficient price history for calculation.
Growth & Income
Revenue growth year-over-year has contracted by -43.9%, while earnings growth is N/A due to the persistent negative earnings position, indicating that the company is currently in a phase of contraction rather than expansion. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute income to shareholders, implying that any retained earnings are theoretically intended for reinvestment into research and development, although current cash burn suggests a need for external capital raising. The overall growth and income profile is characterized by significant revenue contraction, negative profitability, and a complete absence of dividend income, presenting a high-risk scenario typical of early-stage or distressed biotechnology companies.